Defining Characteristics of Types I and II Apoptotic Cells in Response to TRAIL  by Özören, Nesrin & El-Deiry, Wafik S.
Defining Characteristics of Types I and II Apoptotic Cells in
Response to TRAIL
Nesrin O¨zo¨ren and Wafik S. El-Deiry
Laboratory of Molecular Oncology and Cell Cycle Regulation, Howard Hughes Medical Institute, Departments of
Medicine, Genetics, and Pharmacology, University of Pennsylvania School of Medicine, Philadelphia, PA 19104,
USA
Abstract
Type I cells have been defined to be independent of
mitochondria for the induction of Fas death receptor–
mediated apoptosis, whereas Type II cells are mitochon-
dria-dependent. Knock-out studies in mice show that
thymocytes are Type I and liver cells are Type II. We have
previously shown that primary human hepatocytes and
HCT116 human colon carcinoma cells behave like Type
II cells because TRAIL- induced apoptosis can be
blocked by the caspase 9 inhibitor, Z-LEHD-FMK. On
the other hand, caspase 9 inhibition does not allow
survival of TRAIL-treated SW480 colon cancer cells,
which is predicted for Type I cells. Investigating the
differences in TRAIL- induced apoptotic pathways in
HCT116 and SW480 cells revealed that although FADD,
BID, and procaspase 3 protein levels are higher in
SW480 cells, and although procaspase 8 and FLIP
processing is more efficient at the TRAIL-DISC of
SW480 cells, BID, procaspase 3, XIAP, and PARP
cleavages occur more rapidly in HCT116, despite the
higher levels of BCL-2 and HSP70. Cytochrome c
release from the mitochondria to the cytoplasm is more
efficient in HCT116 cells. These results suggest BID
cleavage as a possible limiting factor in the involvement
of mitochondria in TRAIL- induced cell death. Thus,
regulation of BID cleavage may define if a cell is
mitochondria-dependent or - independent in response
to TRAIL death receptor–induced apoptosis.
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Introduction
TRAIL is a membrane- incorporated trimeric ligand, which
binds two proapoptotic death receptors, DR4 and KILLER/
DR5, and two antiapoptotic decoy receptors, DcR1 (TRID)
and DcR2 (TRUNDD). The interaction between the ligand
and its death receptors leads to the assembly of a multi-
component death- inducing signaling complex (DISC) at the
cell membrane. The adaptor FADD provides a bridge bet-
ween the death receptors and the initiator procaspase 8
[1]. Procaspase 8 autocatalytically activates itself by cleav-
ing the p10 and p20 subunits off the full - length zymogen.
Active caspase 8 then can cleave and activate the effector
caspases 3, 6, and 7. This axis from the cell membrane to
apoptosis is referred to as the ‘‘extrinsic pathway.’’ Many
kinds of cellular stress, including starvation, oxidative
damage, and DNA damage, are known to initiate another
death axis known as the ‘‘intrinsic pathway’’ where caspase
activation follows signals transduced at the level of the
mitochondria. The critical event appears to be the release
of cytochrome c from the intermembrane space of mito-
chondria into the cytoplasm, where, together with Apaf 1
and procaspase 9, the apoptosome is formed. At the
apoptosome, the initiator procaspase 9 becomes activated
and further can cleave downstream effector caspases,
including caspase 3, which can actually cleave procaspase
8 engaging the extrinsic cascade in an amplification loop.
Another cross- talk between the two axes was found when
it was discovered that BID, when cleaved by caspase 8, is
capable of translocating into mitochondria and signaling
cytochrome c release [2].
There are both positive and negative regulators of the
intrinsic and extrinsic cell death pathways, emphasizing the
importance of apoptosis regulation. At the level of initiator
caspases, cellular FLIP is capable of binding FADD,
generally accepted to be competing for DISC binding with
procaspase 8 [3]. A large family of regulators is the BCL-2
family, which includes both positive regulators such as BAX,
BAK, and BID and antiapoptotic molecules such as BCL-2
and BCL-XL [4]. These antiapoptotic molecules are capable
of delaying or preventing cytochrome c release in response to
both intrinsic or extrinsic death inducers, whereas proapop-
totic members have the opposite effect. Recently, it was
found that several heat shock proteins are capable of
regulating apoptotic events positively or negatively. HSP27
has been shown to bind cytochrome c, thus lowering the
levels of cytochrome c available for apoptosome formation
[5]. HSP70 and HSP90 can interact with Apaf 1 directly,
thereby obstructing apoptosome formation [6–8]. The in-
hibitor of apoptosis protein ( IAP) family of antiapoptotic
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regulators includes IAP-1, IAP-2, XIAP, NIAP, BRUCE, and
survivin. Cellular IAPs bind effector caspases [9] and block
their activity [10]. The activity of IAPs is neutralized by
SMAC/DIABLO, a small molecule released from mitochon-
dria along with cytochrome c. SMAC/DIABLO binds IAPs
and thus releases active caspases [11,12].
When the importance of mitochondria in death receptor–
mediated apoptosis was investigated, it became clear that
some cells, called Type I, are independent of mitochondria in
Fas- induced apoptosis. On the other hand, in other cells,
mitochondrial involvement is crucial; these cells are known
as Type II [13]. In the initial paper defining these cell types,
BCL-2 overexpression was used to group the mitochondria-
dependent and - independent cells [14]. Although the phy-
siological relevance of this system is still debated, studies in
knock-out mice have provided convincing evidence that
there may be tissues geared to respond in a Type I versus
Type II manner. For example, hepatocytes from Bid / 
mice are resistant to the Fas-activating antibody in vivo but
their thymocytes are still sensitive to Fas [15]. Hepatocytes
from Bax /  Bak /  mice are also resistant to Fas, with
their thymocytes being sensitive to Fas but resistant to eto-
poside and radiation [16]. Thymocytes from Apaf 1 /  and
caspase 9 /  mice are also sensitive to Fas but resistant
to DNA-damaging agents, such as etoposide, dexametha-
sone, and g - radiation [17,18]. Thus, in mice, thymocytes
are Type I cells, whereas hepatocytes are prototypical
mitochondria-dependent, Type II cells. The mechanism for
the difference in use of the intrinsic and extrinsic pathways
is not understood. It has been suggested that the levels of
activated caspase 8 generated at the DISC may define the
necessity for mitochondrial involvement [14].
We have shown that primary human hepatocytes behave
in a Type II manner, such that inhibition of caspase 9 by Z-
LEHD-FMK leads to the prevention of TRAIL- induced
apoptosis. Among the different cell lines tested, HCT116
cells responded similar to the hepatocytes, whereas SW480
cells did not survive after TRAIL treatment in the presence of
the caspase 9 inhibitor [19]. Furthermore, HCT116 cells
deficient for BAX are resistant to TRAIL- induced apoptosis
[20]. Both SW480 and HCT116 come from the colon, and it
is counterintuitive that the same tissue should develop
different strategies of apoptosis induction to the same signal.
Nevertheless, it is possible that the different conditions,
under which the cells became cancerous, may have in-
fluenced the levels of different proapoptotic and antiapoptotic
regulators, leading to the prevalence of the intrinsic or
extrinsic pathways. Taking into account this limitation, we
undertook to investigate the differences between the
apoptotic pathways of SW480 and HCT116 cells. We report
that endogenous FADD, BID, and procaspase 3 protein
levels are higher in SW480 cells, and the processing of pro-
caspase 8 and FLIP is more efficient at the DISC of SW480
cells. This is interesting because the timing of BID, pro-
caspase 3, XIAP, and PARP depletion is faster in HCT116
cells, despite the higher levels of the negative regulators
BCL-2 and HSP70. Further, cytochrome c release is slower
in SW480 cells. Thus, it appears that the limiting step for
mitochondrial involvement in SW480 cells upon TRAIL treat-
ment may be the cleavage of BID.
Materials and Methods
Cell Lines
The human colon cancer cell line SW480 and the human
lymphocytic cell line SKW6.4 were obtained from the ATCC
(Manassas, VA). The human non small cell lung cancer cell
line H460 was obtained from Dr. Stephen Baylin (Johns
Hopkins University, Baltimore, MD) and the human colon
cancer cell line HCT116 was obtained from Dr. Bert
Vogelstein (Johns Hopkins University ). HCT116 cells were
grown in McCoy’s 5A medium, SW480 in DMEM (high
glucose), and H460 in RPMI 1640, each supplemented with
10% fetal bovine serum and 1% penicillin /streptomycin. All
media were purchased from Gibco BRL-Life Technologies
(Rockville, MD). The cells were grown at 378C with 5% CO2.
NHH#2 (normal human hepatocytes, sample #2) were
isolated from the liver of a 9-year-old boy, who died in a
house fire, as described in Ref. [19]. NKNT-3 cells (normal
human hepatocytes immortalized with the SV40 T antigen)
were obtained from Dr. Ira Fox (University of Nebraska,
Omaha, NE). NHH#2 and NKNT-3 cells were grown in CS
Complete Serum Free Medium (Cell Systems Corp., Seattle,
WA).
Western Analyses
Cell lysates were analyzed on 10% or 15% SDS-PAGE
and probed with the following antibodies (Ab), at the given
dilutions (vol /vol ): anti–actin monoclonal mouse Ab-1/250
(Santa Cruz Biotechnology, Santa Cruz, CA); anti–BID
rabbit polyclonal Ab-1/500 (BD PharMingen, San Diego,
CA); anti–BID rabbit polyclonal -1500 or 1/1000 (Cell
Signaling Technology, Beverly, MA); anti–BCL-2 mouse
monoclonal Ab-1/500 (DAKO, Glostrup, Denmark); anti–
BCL-XL mouse IgG-1/500 (BD PharMingen); anti–cIAP1
and anti -cIAP2 rabbit IgGs-1/1000 (R&D Systems, Minne-
apolis, MN); anti–XIAP(hILP) mouse IgG-1/250 (Trans-
duction Laboratories, Lexington, KY); anti–FADD mouse
IgG-1/2000 (Upstate Biotechnologies, Lake Placid, NY);
anti–FLIP rat IgG-1/1000 (Alexis, San Diego, CA); anti–
caspase 3 (E-8) mouse IgG-1/500 (Santa Cruz Biotech-
nology); anti–caspase 8(1C12) mouse IgG-1/1000 (Cell
Signaling Technology); anti–caspase 9 rabbit polyclonal
Ab-1/500 (BD PharMingen); anti–cleaved caspase 9
polyclonal rabbit Ab-1/500 (Cell Signaling Technology);
anti–HSP27 mouse, anti–HSP70 mouse, and anti–HSP90
rat IgGs-1/1000 each (StressGen Biotechnologies, Victor-
ian BC, Canada); anti–PARP polyclonal rabbit Ab-1/2000
(Roche, Mannheim, Germany); and anti–cytochrome c
mouse monoclonal Ab-1/1000 (BD PharMingen).
Immunoprecipitation of TRAIL-DISC
Cells from confluent T75 flasks (>4107) were collected
by trypsinization and treated with 50 ng/ml 6 His-TRAIL
(R&D Systems) in a total volume of 2 ml in the respective
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growth medium for the cells. The anti -6 Histidine mouse
IgG (R&D Systems) was added to both control and test
samples at 1 g/ml. The cells were incubated at 378C for 15
or 30 minutes, as indicated in the figure legends, and the
reaction was stopped by the addition of ice-cold 1 PBS to
the reaction tubes. The DISC immunoprecipitation buffers
and protocols were modified from Sprick et al. [21]. The
TRAIL-DISC buffer used consisted of 30 mM Tris (pH 7.5),
150 mM NaCl, 10% (vol /vol ) glycerol, and 1% (vol /vol )
Triton X-100. The cells were lysed on ice in 1 ml of ice-cold
TRAIL-DISC buffer supplemented with Complete (protease
inhibitor cocktail ) as directed by the manufacturer (Roche)
and 1 mM PMSF for greater than 30 minutes. The debris was
pelleted twice after which 3% of the supernatant was saved
for analysis as a total lysate control. To the rest of the
supernatant, 30 l of Protein A/G PLUS-Agarose (Santa
Cruz Biotechnology) was added. The incubation of the
beads with the lysates continued at 48C for 48 hours in
constant rotation. The beads were pelleted and washed four
times with 700 l of ice-cold TRAIL-DISC buffer, after which
the beads were eluted in 175 l of Immunopure Gentle Ab/
Ag Elution Buffer (Pierce, Rockford, IL), supplemented with
0.1 M DTT, at room temperature for greater than 2 hours.
The beads were pelleted and the proteins in the supernatant
were precipitated using methanol–40% (vol /vol ) /chloro-
form–10% (vol /vol ) extraction. The protein precipitate was
resuspended in 2 Laemmli buffer and analysed further by
Western blotting.
TRAIL Treatment Time Course
A total of 1.5106 cells were plated per T25 1 day ahead
of treatment. Cells were treated with 50 ng/ml TRAIL (R&D
Systems) in the presence of the cross- linking anti -6 His
antibody at 1 g/ml. The cross- linking antibody was present
in the control sample as well. Where caspase inhibitors were
used, their final concentration was 20 M. For the com-
bination of caspases 2 and 9 inhibitors, each was present at
10 M. The caspase 8 inhibitor Z- IETD-FMK, the caspase 2
inhibitor Z-VDVAD-FMK, the caspase 9 inhibitor Z-LEHD-
FMK, and the pan caspase inhibitor Z-VAD-FMK were
purchased from R&D Systems. The incubation continued
for 4, 8, or 24 hours at 378C, after which the attached and
the floating cells were collected and analyzed by Western
blotting.
Cellular Fractionation
Confluent T75 flasks (>107 cells ) of HCT116 and SW480
were treated with His-TRAIL (Alexis) at 100 ng/ml in the
presence of the cross- linking anti–Histidine Ab at 1g/ml for
4 hours in a total volume of 5 ml per flask. The floating and
the attached cells were collected through trypsinization. The
cells were lysed in 68 mM sucrose, 200 mM D-mannitol,
Figure 1. Endogenous levels of FADD, BID, and procaspase 3 are higher in SW480 cells. Procaspase 8 and FLIP processing at the TRAIL -DISC. (A ) Western
analysis of the endogenous levels of the indicated proteins in NHH-2, NKNT -3, SW480 and HCT116 cells. (B ) The cells were treated with His -TRAIL for
15 minutes (upper panel ) or 30 minutes ( lower panel ) in the presence of the cross - linking antibody. The TRAIL -DISC complex was immunoprecipitated and
tested for the presence of procaspase 8, FADD, and FLIP. ‘‘M’’ stands for mock, and ‘‘TR’’ or ‘‘T’’ for TRAIL treatment, as described in Materials and Methods.
Neoplasia . Vol. 4, No. 6, 2002
Characteristics of Types I and II Apoptotic Cells O¨zo¨ren and El -Deiry 553
50 mM KCl, 1 mM EGTA, 1 mM ETDA, 1 mM DTT, 1 mM
PMSF, and Complete protease inhibitor cocktail as directed
by the manufacturer (Roche). The cells were first lysed on
ice for 80 minutes and then through 40 strokes of a Dounce
homogenizer. The lysates were centrifuged at 2700 rpm for
5 minutes in a Beckman SS34 rotor to obtain the nuclear /
whole cell fraction. The pellets were washed once in
the same lysis buffer and collected in the same way. The
supernatants, containing the heavy membrane and the
cytosolic fractions, were centrifuged at 11,000 rpm for 10
minutes in the same rotor to obtain the heavy membrane
fraction. The heavy membrane pellet was washed once and
recovered under the same conditions. The cytosolic fraction
was precipitated from the supernatant using 6 vol of 50%
ethanol, 25% methanol, and 25% acetone, prechilled to
808C. The precipitation was allowed to occur at 808C
overnight. The cytosolic fraction was pelleted by centrifuga-
tion in 1.5-ml tubes in a microfuge at 10,000 rpm for 10
minutes at 48C. The pellet was rinsed once in the above
described precipitation solution and recovered through
centrifugation. The pellets were air -dried and resuspended
in 2 Laemmli buffer. All the fractions were subjected to 15%
SDS-PAGE and Western analysis.
Results
Endogenous Levels of FADD, BID, and Procaspase 3 are
Higher in SW480 Versus HCT116 Cells
Semiquantitative RT-PCR analysis of DR4, KILLER/
DR5, DcR1, and DcR2 levels in HCT116 and SW480 cells
has shown that both cell lines express high levels of all four
receptors, relative to other tested cell lines [22]. HCT116
and SW480 are highly sensitive to TRAIL and even at
20 ng/ml, greater than 50% Annexin V–positive cells can be
observed after a 4-hour incubation time [19]. We focused on
the intracellular apoptotic pathway components to identify
differences between the two cell lines. Western blot analysis
(Figure 1A ) shows that SW480 cells have higher endoge-
nous levels of FADD, BID, and procaspase 3. The presence
of high levels of FADD and procaspases 8 fits with the
expectations for a Type I cell. High FADD and procaspase 8
levels would provide adequate substrates for the TRAIL-
DISC (see below), giving rise to large amounts of active
caspase 8, which could act directly on the abundant
procaspase 3, thus minimizing the necessity for the mito-
chondrial amplification loop even if it does take part.
Procaspase 8 and Flip Processing are More Efficient at the
TRAIL-DISC of SW480 Versus HCT116 Cells
It had been suggested that low levels of procaspase 8
recruitment to the DISC in Type II cells make the
mitochondrial loop necessary for generating enough active
caspase 8 [14]. We tested if the difference in the apoptotic
pathways in HCT116, SW480, and H460 could be accounted
for by the relative levels of procaspase 8, FADD, and FLIP or
by the processing of procaspase 8 and FLIP at the DISC.
The protein levels of FADD and procaspase 8 being higher in
SW480 cells, one would expect that there would be more of
these proteins at the TRAIL-DISC of SW480 cells. By
immunoprecipitating the TRAIL-DISC, we were able to show
that FADD, procaspase 8, and FLIP are present at the
TRAIL-DISC (Figure 1B ). By comparing the relative amount
of procaspase 8 in SW480, H460 (Type I– like) versus
HCT116 (Type II– like) cells, it is not possible to conclude
that there is more procaspase 8 recruited to the DISC of
Type I– like cells. It may be expected that there should be
more FLIP at the TRAIL-DISC of HCT116 cells to obstruct
Figure 2. Timing of BID, procaspase 3, and PARP cleavage in SW480 and HCT116 cells after TRAIL treatment. (A ) The cells were treated with TRAIL in the
presence of the different inhibitors for the indicated times — 4, 8, and 24 hours. The molecular composition of the different caspase inhibitors is given in Materials
and Methods. BID cleavage was analyzed through Western analysis. (B ) The cleavages of procaspase 3 and PARP were tested after 4, 8, and 24 hours of TRAIL
treatment. Different caspase inhibitors were used to show the difference in their effects on procaspase 3 and PARP cleavage in HCT116 and SW480 cells. Caspases
9 and 2 inhibitors prevent procaspase 3 and PARP cleavages in HCT116 cells ( see 8 -hour time point ). ‘‘M’’ stands for mock, and ‘‘T’’ or ‘‘Tr’’ for TRAIL treatment.
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the generation of active caspase 8, but on the contrary, H460
and SW480 cells have larger amounts of FLIP and still the
processed caspase 8 and FLIP bands are stronger (Figure
1B ). It appears that the presence of full - length FLIP does not
impede the efficiency with which the small subunit is cleaved
off procaspase 8. Another interesting aspect of the SW480
DISC is that FADD levels are lower than observed in
HCT116 cells. Higher FADD and lower FLIP levels may be
expected to facilitate procaspase 8 activation; however, just
the opposite appears to be the case. Low FADD and high
FLIP levels in SW480 appear to coexist with the quick pro-
cessing of both FLIP and procaspase 8 (Figure 1B ). This
suggests that while in its full - length form, FLIP may have a
positive effect on caspase 8 activation. When the caspase 8
activity in TRAIL- treated cell lysates was compared, the
IETD-pNA cleaving activity in SW480 cells was higher (data
not shown).
The Cleavage of BID, Procaspase 3, and PARP is Faster in
HCT116 Versus SW480 Cells
Because the efficiency of caspase 8 activation appears
higher at the TRAIL-DISC of SW480 versus HCT116, we
hypothesized that procaspase 3 and PARP cleavages
should be faster in SW480 cells. Surprisingly, the cleavages
of BID (Figure 2A ), procaspases 3, and PARP (Figure 2B )
appear to occur more rapidly in HCT116 cells because at 4
hours after TRAIL treatment, there is a clear reduction in the
levels of their native forms. SW480 cells deplete the same
molecules substantially by 8 hours (Figure 2). Thus, the
endogenous levels of the proteins or the efficiency of
caspase 8 activation at the DISC does not correlate with
the timing of BID, procaspase 3, and PARP cleavage. These
results point to BID cleavage as the step where SW480 cells
fail to activate mitochondria as effectively as HCT116 cells.
When the effect of the different caspase inhibitors is
examined, it becomes clear that the caspase 8 inhibitor, Z-
IETD-FMK, is capable of blocking procaspase 3 and PARP
cleavages in both cell lines even at 24 hours. The caspases 2
and 9 inhibitors can prevent procaspase 3 and PARP
cleavage much better in HCT116 than SW480 cells (Figure
2B and Ref. [19] ).
BCL-2 and HSP70 Levels are Higher in HCT116 Cells;
XIAP is Cleaved Faster in TRAIL-Treated HCT116 Cells
Because apoptotic pathways are tightly regulated by
positive and negative regulators, we checked if HCT116 and
SW480 cells have different levels of the negative regulators
acting on mitochondria: BCL-2 and BCL-XL; the caspase
inhibitors IAP-1, IAP-2, and XIAP; and the apoptosome
inhibitors HSP27, HSP70, and HSP90 (Figure 3). Among
these, BCL-2 and HSP70 levels are higher in HCT116 cells.
Like BID, procaspase 3, procaspase 9, and PARP, XIAP
cleavage is also faster in HCT116 cells (Figure 3B ). This
suggests that once activated, the HCT116 mitochondria
have the ability to initiate downstream events in spite of the
higher levels of negative regulators BCL-2 and HSP70.
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Figure 4. Cytochrome c release from mitochondria after TRAIL treatment in
SW480 and HCT116 cells. Nuclear, heavy membrane, and cytosolic
fractions were obtained after TRAIL treatment as described in Materials
and Methods. The different fractions were analyzed for procaspase 8, BID,
and cytochrome c. ‘‘M’’ stands for mock, and ‘‘Tr’’ for TRAIL treatment.
Figure 3. Endogenous levels of antiapoptotic regulators and timing of XIAP
cleavage. (A ) Endogenous levels of the indicated antiapoptotic regulators
were tested through Western analysis. (B ) Timing of XIAP cleavage after
TRAIL treatment. ‘‘M’’ stands for mock, and ‘‘Tr’’ for TRAIL treatment.
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Cytochrome c Release is Faster in HCT116 Versus SW480
Cells
To test if the limiting event is BID cleavage, we checked
the release of cytochrome c from the mitochondria upon
TRAIL treatment. We observed a clear accumulation of
cytochrome c in the cytosolic fraction of TRAIL- treated
HCT116 cells, but not in SW480 cells (Figure 4). As
expected, there was a dramatic reduction in the BID levels
in the cytosolic fraction of HCT116 cells. The truncated form
of BID accumulated in the heavy membrane fraction after
TRAIL treatment but was not detectable in the cytosolic
fraction. We also tested the levels of procaspase 8 and its
cleaved form in the different fractions (Figure 4). It is clear
that the levels of active caspase 8 are not lower in SW480
cells, and still BID cleavage is not efficient.
Discussion
So far, the reason for the preferential use of the intrinsic or
extrinsic pathways in different tissues in response to death
receptor activation is not clearly understood. We find that
although FADD, BID, and procaspase 3 levels are higher in
SW480 cells and although the processing of procaspase 8
and FLIP is more efficient at the TRAIL-DISC of SW480
cells, the cleavages of BID, procaspase 3, XIAP, and
PARP occur more rapidly in HCT116 cells, despite higher
BCL-2 and HSP70 levels. These results suggest that BID
cleavage is the limiting step in SW480 cells. This notion is
supported by the slower rate of cytochrome c release
observed in SW480 cells. Because the pNA-IETD cleaving
activity in SW480 cells is higher in SW480 cells (data not
shown), it is unlikely that the reason for the inefficient BID
cleavage is the lack of caspase 8 enzymatic activity.
However, it is possible that the interaction between the two
molecules is different in the two cell lines. The interaction
between caspase 8 and BID can be influenced by: 1) a
posttranslational modification of BID, besides myristoyla-
tion; 2) the presence of a negative regulator in SW480
cells; 3) the presence of a positive regulator in HCT116
cells; and 4) a mutation in BID, so that the physical inter-
action is affected.
Besides the cleavage of BID by caspase 8 [2] and
myristoylation of tBID [23], tBID has been reported to be
ubiquitinated and targeted for degradation. When the
putative ubiquitination sites within tBID were mutated, the
nondegradable tBID induced stronger cytochrome c release
[24]. Phosphorylation of BID by casein kinases I and II (CKI
and CKII ) has been very recently demonstrated to regulate
its cleavage by caspase 8. A mutant form of BID, which could
not be phosphorylated, was more easily cleaved by caspase
8 and was also more toxic to cells that the wild type form
[25], suggesting that phosphorylation is inhibitory to caspase
8 cleavage.
Our results point to BID as a possible determinant for the
choice of a Type I or II mechanism in response to death
receptor–mediated signaling. In SW480 and HCT116 cells,
the rate of BID cleavage appears to define the ability of the
cells to activate mitochondrial cytochrome c release.
We suggest that different tissues have developed or
optimized the use of the intrinsic or extrinsic pathway
dependent on their normal functions. For example, liver cells
are responsible for the detoxification of many chemicals that
enter the blood, and many cytotoxic and genotoxic agents
are known to activate the intrinsic pathway predominantly.
Thymocytes or other cells responsible for immune responses
are actually expected to signal to each other and to target
cells through membrane-bound ligands, such as FAS-L or
TRAIL, or secreted cytokines, and thus these cells have
optimized the extrinsic apoptotic pathway. Based on this
hypothesis, colon and kidney cells would be expected to be
Type II cells also.
Knowing the mechanism by which death is propagated in
different tissues would allow the design of better and
targeted strategies for killing cancer cells and protecting
normal cells. We have developed one such strategy for the
protection of human liver [19]. We propose that treatment of
Type I tumor cells with TRAIL in the presence of caspase 9
and/or caspase 2 inhibitors would allow the killing of the
tumor cells while protecting the liver cells in vivo. TRAIL
toxicity is an issue to be considered for the liver but not
other primary human tissues, based on studies performed
so far. A preliminary study by our group provides evidence
that the proposed strategy is applicable to a second tissue,
the esophagus (Kim KH, et al., submitted for publication).
Primary human esophageal cells act in a Type II manner.
When grown in a mixed population with Type I cancer cells
and treated with TRAIL in the presence of a caspase 9
inhibitor, the cancer cells are killed, whereas the primary
esophageal cells are protected. Our present studies provide
further insights into the signaling pathways that govern cell
death following TRAIL exposure.
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